Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
66
ABOS Quote, Financials, Valuation and Earnings
Last price:
$2.14
Seasonality move
:
-5.23%
Day range:
$2.11 - $2.28
52-week range:
$0.86 - $2.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.40x
Volume:
264K
Avg. volume:
164.8K
1-year change:
19.44%
Market cap:
$130.2M
Revenue:
--
EPS (TTM):
-$2.21
Analysts' Opinion
-
Consensus RatingAcumen Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.40, Acumen Pharmaceuticals, Inc. has an estimated upside of 197.67% from its current price of $2.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $2.15.
Fair Value
-
According to the consensus of 6 analysts, Acumen Pharmaceuticals, Inc. has 197.67% upside to fair value with a price target of $6.40 per share.
ABOS vs. S&P 500
-
Over the past 5 trading days, Acumen Pharmaceuticals, Inc. has overperformed the S&P 500 by 0.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Acumen Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Acumen Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Acumen Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Acumen Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Acumen Pharmaceuticals, Inc. reported earnings per share of -$0.44.
Enterprise value:
34.5M
EV / Invested capital:
0.28x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-0.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$183K
Return On Assets:
-65.08%
Net Income Margin (TTM):
--
Return On Equity:
-87.18%
Return On Invested Capital:
-72.85%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$194K | -$173K | -$183K | -$45K | -$47K | |
| Operating Income | -$56.9M | -$92.9M | -$138.2M | -$32.3M | -$26.5M | |
| EBITDA | -$56.7M | -$92.7M | -$138M | -$32.2M | -$26.5M | |
| Diluted EPS | -$1.11 | -$1.37 | -$2.21 | -$0.50 | -$0.44 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $204.9M | $202.6M | $218.6M | $207.6M | $132.2M | |
| Total Assets | $234.8M | $203.3M | $286.4M | $267M | $142.2M | |
| Current Liabilities | $1.5M | $6.6M | $6.1M | $19.9M | $22M | |
| Total Liabilities | $1.5M | $6.6M | $6.1M | $49.8M | $49M | |
| Total Equity | $233.4M | $196.7M | $280.3M | $217.2M | $93.2M | |
| Total Debt | -- | -- | -- | $29.9M | $30.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$46M | -$67.3M | -$123.7M | -$24.6M | -$30.5M | |
| Cash From Investing | -$143.3M | -$30.4M | $137.3M | -$10.1M | $40.5M | |
| Cash From Financing | $126.8M | $36.1M | -$45K | -$42K | -- | |
| Free Cash Flow | -$46M | -$67.3M | -$123.7M | -$24.6M | -$30.5M | |
ABOS
Sector
Market Cap
$130.2M
$27.9M
Price % of 52-Week High
87.4%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-0.17%
-1.49%
1-Year Price Total Return
19.44%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.06
200-day SMA
Buy
Level
$1.44
Bollinger Bands (100)
Buy
Level
1.38 - 2.04
Chaikin Money Flow
Sell
Level
-4.4M
20-day SMA
Buy
Level
$1.94
Relative Strength Index (RSI14)
Buy
Level
59.46
ADX Line
Buy
Level
19.8
Williams %R
Neutral
Level
-24.5283
50-day SMA
Buy
Level
$1.98
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
104.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.6376)
Sell
CA Score
(Annual)
Level (-0.8812)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.6812)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.
Stock Forecast FAQ
In the current month, ABOS has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABOS average analyst price target in the past 3 months is $6.40.
-
Where Will Acumen Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Acumen Pharmaceuticals, Inc. share price will rise to $6.40 per share over the next 12 months.
-
What Do Analysts Say About Acumen Pharmaceuticals, Inc.?
Analysts are divided on their view about Acumen Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Acumen Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Acumen Pharmaceuticals, Inc.'s Price Target?
The price target for Acumen Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $6.40 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABOS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Acumen Pharmaceuticals, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABOS?
You can purchase shares of Acumen Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Acumen Pharmaceuticals, Inc. shares.
-
What Is The Acumen Pharmaceuticals, Inc. Share Price Today?
Acumen Pharmaceuticals, Inc. was last trading at $2.14 per share. This represents the most recent stock quote for Acumen Pharmaceuticals, Inc.. Yesterday, Acumen Pharmaceuticals, Inc. closed at $2.15 per share.
-
How To Buy Acumen Pharmaceuticals, Inc. Stock Online?
In order to purchase Acumen Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ABOS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABOS
Sector
P/E ratio
--
23.85x
PEG ratio
-0.02x
-0.01x
P/B ratio
1.40x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
ABOS
Sector
Revenue growth
--
4.62%
Earnings growth
11.85%
10.5%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$0.68
-$0.21
Profitability
ABOS
Sector
Profitability FY 2024
-$178K
$3.6M
Return on invested capital
-72.85%
-31.87%
Return on assets
-65.08%
-28.18%
Return on equity
-87.18%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
11
Balance Sheet
ABOS
Sector
Total cash
$126.6M
$26.4M
Short term investments
$135.9M
$25.7M
Total assets
$239M
$76.9M
Long term debt
$30.7M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
